Coagulation plays a role in ischemic heart disease (IHD). However, which coagulation factors are targets of intervention is unclear.
C
ardiovascular disease is the leading cause of mortality globally. 1 Despite substantial progress in prevention and control, the cause of cardiovascular disease is not completely understood, 2 as evidenced by the challenges of developing new cardiovascular therapeutics. 3 Thrombosis can be an important step in the pathogenesis of ischemic heart disease (IHD), involving platelets and a coagulation cascade. 4 Specifically, after injury, platelets adhere to collagen and vWF (von Willebrand factor) in subendothelial tissue, where vWF acts as a bridge between endothelial collagen and platelet surface receptors. Activated platelets release stored granules, such as ADP and thromboxane A 2 , stimulating platelet aggregation. 4 Coagulation activation proceeds through activation of proteases; factor Xa (activated factor X) initiates the final common pathway in the cascade and results in the formation of thrombin. 4 Thrombin is central to the clotting process: it converts soluble fibrinogen to fibrin; activates FV, FVIII, and FXI generating more thrombin; stimulates platelets; and favors the formation of cross-linked bonds among the fibrin molecules by activating FXIII, which stabilizes the clot. 5 Cofactors are also involved in the cascade, including vitamin K, and in the fibrinolysis, such as PAI (plasminogen activator inhibitor), fibrinogen, and d-dimer. 4 Systematic reviews and meta-analyses of observational studies have shown that coagulation and fibrinolysis factors, including fibrinogen, vWF, d-dimer, tPA (tissue-type plasminogen activator) antigen, and PAI-1, are associated with IHD. [6] [7] [8] Observational studies are open to residual confounding, making them difficult to use as a basis for action. 9 Moreover, coagulation factors are closely correlated and related to inflammation, 10 so separating their roles is challenging in observational studies. Candidate gene studies have shown that genetic variants, such as rs6025 in the FV gene (F5) and rs1799963 in the prothrombin gene (F2), increase circulating thrombin generation and are associated with IHD. 6 However, candidate gene studies are open to selective reporting. Currently, the clinical effectiveness of anticoagulation agents, including the antithrombin DNA aptamer NU172, 11 the anti-FIXa aptamer REG1, 11 and anti-vWF agents, 12 is being tested in clinical trials, although these trials were not preceded by genetic validation.
In this situation, comparing cardiovascular events according to naturally occurring genetic variants related to coagulation factors, that is, Mendelian randomization (MR), provides a means of examining causal effects, without any potentially harmful intervention. 9 To examine the role of coagulation factors, we searched systematically for genome-wide association studies (GWAS) of major coagulation factors, that is, vWF, thrombin generation potential, FV, FVII, FVIII, FXa, tPA, PAI-1, d-dimer, and thromboxane. We examined their role in coronary artery disease (CAD)/myocardial infarction (MI), a composite of stable CAD and acute MI, and MI, using very large case-control studies of CAD/MI and MI with extensive genotyping. [13] [14] [15] To determine whether any associations were independent of lipids, we similarly examined their role in lipids using a very large study providing genetic associations with lipids. 16 Finally, we assessed whether any of the key genes relevant to these coagulation factors, that is, potential genetic targets of intervention, were strongly associated with IHD.
METHODS
The data and methods are publicly available. We searched Pubmed and LD Hub systematically for GWAS giving singlenucleotide polymorphisms (SNPs) reaching GWAS significance (5×10 −8 ) for the coagulation factors, that is, vWF, thrombin generation potential, FV, FVII, FVIII, FXa, tPA, PAI-1, d-dimer, and thromboxane. Novel SNPs showing promising associations (P value <5×10 −5 ) were also used, but excluded in sensitivity analysis. To ensure that the selected SNPs were solely associated with CAD/MI or MI via the relevant exposures, we checked for pleiotropy, that is, genetic associations with CAD/ MI or MI via other phenotypes, using 2 comprehensive genetic
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3 cross-reference systems, Ensembl (http://www.ensembl.org/ index.html) and PhenoScanner (www.phenoscanner.medschl. cam.ac.uk), which provide all known well-established associations of SNPs with phenotypes, including subgenome-wide associations. 17 We also checked for linkage disequilibrium (LD), using Ensembl 16 We obtained the associations of coagulation factors with CAD/MI and MI from separate sample instrumental variable analysis. Where a SNP predicting a coagulation factor was not available for the outcomes, we sought a highly correlated proxy (r 2 ≥0.8). We aligned SNPs based on allele letter and frequency. We obtained SNP-specific Wald estimates (ratio of the genetic association with CAD/MI or MI to the genetic association with exposure) and the ratio SD using Fieller's theorem. 18 We combined SNP-specific estimates using inverse variance weighting with fixed effects, for uncorrelated SNPs, 19 and weighted generalized linear regression, for correlated SNPs. 19 We checked for replication in independent studies for each SNP and conducted sensitivity analysis only using the replicated SNPs. To account for potential bias from unknown pleiotropy, we conducted sensitivity analyses using a weighted median (in uncorrelated SNPs) and MR Egger (if >3 SNPs predicted the exposure), 20 which are more robust to pleiotropy. We checked whether the intercept from MR Egger was nonzero because this indicates that some genetic predictors might be acting other than via the exposure (ie, directional pleiotropy). 20 We also checked whether coagulation-related genes (vWF for vWF; F2, F2R, F2RL1, F2RL2, and F2RL3 for thrombin; FGB for fibrinogen; F5 for FV; F7 for FVII; F8 for FVIII; F10 for FXa; F11 for FXI; F13A1 for FXIII; PLAT for tPA; SERPINE1 for PAI-1; and TBXAS1 for thromboxane A synthase) were associated with IHD and MI, as potential targets of intervention. For each gene, we assessed whether the distribution of the P values for the associations of the SNPs with CAD/MI or MI differed from the uniform distribution expected by chance, using all the SNPs available in the CARDIOGRAMplusC4D 1000 Genomes for each gene and taking into account correlations between SNPs to obtain an overall P value for the association of the gene with CAD/MI or MI. We used a gene-based association test using extended Simes, which is a Simes test adjusted for the LD of the P values. 21 Gene-based association test using extended Simes has the advantage of not requiring simulations and provides a validated approximation to other methods. 22 The LD was obtained from the 1000 Genomes catalog. All statistical analyses were conducted using R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). This analysis of publicly available data does not require ethical approval.
RESULTS
We obtained genetic predictors, that is, SNPs, for vWF, thrombin generation potential (indicated by ETP [endogenous thrombin potential]), d-dimer, FVIII, tPA, and PAI-1 from GWAS. [23] [24] [25] [26] [27] [28] [29] We could not find GWAS for FV, FVII, FXa, or thromboxane. We identified 20 SNPs for vWF from 3 GWAS, [23] [24] [25] 18 SNPs for ETP from 1 GWAS, 26 3 SNPs for d-dimer from 1 GWAS, 27 10 SNPs for FVIII from 3 GWAS, [23] [24] [25] 4 SNPs for tPA from 1 GWAS, 28 and 8 SNPs for PAI-1 from 1 GWAS. 29 All the GWAS were conducted in people of European ancestry. Table I in the Data Supplement gives associations of these SNPs with the coagulation factors. Genetic predictors for vWF, FVIII, d-dimer, tPA, and PAI-1 used HapMap for imputation [23] [24] [25] [27] [28] [29] and genetic predictors for ETP used 1000 Genomes for imputation. 26 Table II in the Data Supplement gives the genetic associations with CAD/MI in CARDIoGRAMplusC4D Metabochip and 1000 Genomes and with MI in CARDIoGRAMplusC4D 1000 Genomes. Of the 20 SNPs for vWF, 4 SNPs (rs529565, rs379440, rs1438993, and rs2579103) in strong LD were discarded (rs529565 with rs687621, rs379440 with rs13361927, rs1438993 and rs2579103 with rs10745527), giving 16 SNPs for vWF (Table I in the Data Supplement). One SNP (rs687621) for vWF was in the ABO gene and associated with IL-6 (interleukin-6). 30 Given this and the close association of vWF with ABO blood group, 31 estimates including and excluding rs687621 are given for vWF. Of the 18 SNPs for ETP, 2 SNPs (rs60206633 and rs11038982) were discarded because of strong LD (with rs77977823 and rs3136516, respectively), and 1 SNP (rs149327057) was not in the Cardiogram Consortia, nor was its proxy (rs78008827), giving 15 SNPs for ETP. Three SNPs were only weakly correlated (r 2 =0.18 for rs17787912 and rs3136516, r 2 =0.33 for rs3136516 and rs10838599), which was taken into account. Only 1 SNP (rs17787912) for ETP was available in CARDIoGRAMplusC4D Metabochip or CARDIOGRAM, so we only used CARDIoGRAMplusC4D 1000 Genomes. All 3 SNPs for d-dimer were used. Of the 10 SNPs for FVIII, 2 SNPs (rs12557310 and rs2096362) were not in the Cardiogram Consortia, and no proxy SNPs were identified. Two highly correlated SNPs for FVIII (rs216321 [vWF] and rs9390459 [STXBP5]) were also associated with vWF. 23 Two highly correlated ABO SNPs (rs687289 and rs529565) were associated with vWF, ABO blood group, 32 and IL-6. 30 Given the close associations of FVIII with vWF and ABO blood group, 31 estimates including and excluding these SNPs are given for FVIII. Of the 4 SNPs for tPA, 1 SNP (rs2020921) was discarded because of high correlation with rs3136739, giving 3 SNPs for tPA. Of the 8 SNPs for PAI-1, 3 SNPs were discarded because of high correlation (rs6976053 and rs12672665 with rs314376, and rs2075756 with rs3847067), and 2 weakly correlated SNPs (r 2 =0.37 for rs3847067 and rs314376) were retained, giving 5 SNPs for PAI-1. Rs6486122 (ARNTL) for PAI-1, associated with CRP (C-reactive protein), 33 was retained because CRP does not play a causal role in IHD in MR studies. 34 All SNPs for vWF, d-dimer, FVIII, tPA, and PAI-1 were available in the Global Lipids Genetics Consortium Results; however, only 5 SNPs (rs117784795, rs17787912, rs3136516, rs77977823 and rs4752807, proxy SNP for rs35800856) for ETP were available in Global Lipids Genetics Consortium Results.
Genetically predicted vWF was positively associated with CAD/MI and MI (Table 1) , but the associations were null after excluding rs687621 (ABO; Table 1 ). Similarly, genetically predicted FVIII was positively associated with CAD/MI and MI (Table 1 ), but after considering pleiotropy, the association with CAD/MI was null using CARDIoGRAMplusC4D Metabochip, and the association with MI was null using a weighted median and MR Egger (Table 1) . Genetically predicted ETP was positively associated with CAD/MI and MI (Table 1) . Genetically predicted PAI-1 was positively associated with CAD/MI but was not associated with MI (Table 1 ). The associations were in the other direction using MR Egger, where the non-null intercept indicated directional pleiotropy using CARDIoGRAMPLUSC4D 1000 Genomes. The influential genetic predictor, rs314376 (SLC12A9), was detected by Cook's distance and Studentized residual, (Table 1) . Most SNPs for vWF, D-dimer, and PAI-1 have been replicated in independent studies, whereas some SNPs for ETP, FVIII, and tPA located in new loci remain to be replicated (Table I in the Data Supplement). The findings were unchanged using only replicated SNPs, but the associations of FVIII with CAD/MI and MI were null, possibly because of fewer SNPs (Table III in the Data Supplement). The findings were unchanged only using genome-wide significance SNPs (Table IV in the Data Supplement) .
Genetically predicted vWF and FVIII were associated with higher LDL cholesterol and HDL cholesterol using inverse variance weighting, but not after excluding rs687621 (ABO) for vWF and potentially pleiotropic SNPs for FVIII. Genetically predicted FVIII was also associated with lower triglycerides, but not after excluding potentially pleiotropic SNPs. The non-null intercept from MR Egger indicated the presence of directional pleiotropy for the associations of vWF and FVIII with LDL cholesterol; the associations were consistent in MR Egger. Genetically predicted ETP was associated with higher HDL cholesterol, lower LDL cholesterol, and lower triglycerides (Table 2 ). However, the intercept from MR Egger for LDL cholesterol was non-null, and the associations with LDL cholesterol and triglycerides were null using a weighted median. Genetically predicted PAI-1 was positively associated with triglycerides ( Table 2) .
The vWF-related gene, vWF, and 1 thrombin-related gene, F2RL1, were associated with IHD, whereas a different thrombin-related gene, F2, was associated with MI ( Table 3 ). The thromboxane gene (TBXAS1) was strongly associated with IHD and MI. d-dimer-related, tPA-related, and PAI-1-related genes were not associated with IHD or MI. F8 is on the X chromosome, which is not included in the Cardiogram Consortia.
DISCUSSION
In this systematic examination of the role of vWF, ETP, d-dimer, FVIII, tPA, and PAI-1 in IHD and MI using MR consistent with meta-analysis of candidate gene studies, 35 genetically predicted ETP was positively associated with IHD and MI, but not with unhealthy lipids. Genetically predicted vWF was positively associated with IHD, MI, and LDL cholesterol possibly because of rs687621 in the ABO gene. Genetically predicted FVIII was associated with higher IHD, MI, and LDL cholesterol; however, these associations might be because of pleiotropy and were not robust to sensitivity analyses. Genetically predicted PAI-1 was positively associated with IHD but not MI, and associations were not robust to sensitivity analysis. Our study also suggests that d-dimer and tPA might be associated with IHD in observational studies 6, 8 as biomarkers rather than causes of IHD, consistent with their prognostic role. 6, 8 Correspondingly, the PAI-1 and tPA genes were not associated with IHD or MI, but the vWF gene and a thrombin gene were associated with IHD, and another thrombin gene was associated with MI. The thromboxane A 2 gene TBXAS1 was associated with IHD and MI. This is the first study to assess comprehensively the role of coagulation factors in IHD, MI, and lipids using very large samples and methods which provide unconfounded estimates. Genetic variants are randomly allocated at conception and so are less likely to be influenced by the confounders in observational studies, such as lifestyle, health status, socioeconomic position, and use of medication. We used separate samples for coagulation factors and IHD or MI, which reduced the risk of chance associations from the underlying data structure. 36 Nevertheless, several limitations exist. First, genetic predictors for FV, FVII, FXa, and thromboxane A 2 have not been reliably identified. We partially addressed this gap by considering associations of the relevant genes with IHD and MI, which suggested that FV and FXa were unlikely to affect IHD or MI. We could not include platelet response to ADP and other agonists 37 because the effects of the relevant genetic predictors would only be evident in people taking these agonists, which we cannot identify. Second, confounding by population stratification is possible; however, the genetic associations are from studies con- Factor VIII F8 X chromosome n/a n/a n/a n/a ducted in Caucasians, largely of European descent, with genomic control. [13] [14] [15] [23] [24] [25] [26] [27] [28] [29] The same imputation catalog, that is, HapMap CEU, 13, 14, [23] [24] [25] [27] [28] [29] or 1000 Genomes, 15, 26 was used for exposures and IHD. As such, the estimates should not be confounded by population stratification. Confounding by LD is also possible, if the genetic predictor is in LD with a SNP associated with confounders, such as ethnicity. However, our check in 2 comprehensive genetic cross-reference systems did not identify such SNPs. Third, pleiotropy, that is, genetic associations with IHD or MI via other phenotypes than these coagulation factors, might exist. Some SNPs are in functionally relevant genes, such as rs1063857 and rs216321 in vWF for vWF, 23, 25 but some SNPs are in genes with unclear functions, such as rs150611042 in ORM1 for ETP, and rs9399599 in STXBP5 and rs7301826 in STX2 for tPA, which is typical for SNPs selected statistically from GWAS rather than based on biological pathways. 38 Experimental evidence supports associations of the lead SNPs in STXBP5 and STX2 with expression levels of the respective transcripts. 28 The assumptions of MR do not require the SNPs to cause the exposure but to be associated with SNPs that do. 39 We checked for known potential pleiotropy of the SNPs predicting the coagulation factors in 2 comprehensive genetic cross-reference systems including subgenome-wide associations, but the possibility of currently unknown pleiotropic associations remains. However, the findings were consistent only using SNPs replicated in independent studies, adding some validity. We also checked for statistical evidence of unknown pleiotropy using MR Egger, which raised question about the associations of PAI-1 with IHD and MI. Fourth, our study, limited to Caucasians, might not apply to other populations. However, effects of causal factors are not expected to vary by setting, 40 although they might not always be relevant. Fifth, we could not assess whether associations with IHD and MI varied by baseline levels of the coagulation factors. However, observational studies in people with different baseline vWF have shown consistent associations with IHD. 8 Sixth, estimates might be biased if all genetic associations are from a single sample. 36 However, we used different samples for genetic variants on coagulation factors and on IHD, MI, and lipids; the participants only partly overlap for vWF, FVIII, d-dimer, tPA, and PAI-1. As such, any correlation of the genetic variants with unmeasured confounders in the samples with these coagulation factors is unlikely to be replicated in the samples with the outcomes because of the different data structures. 41 Moreover, genetic associations with coagulation factors and with IHD, MI, and lipids all controlled for age and sex (Table I in the Data Supplement), which improved precision of the estimates. Seventh, the small estimate for ETP on IHD and MI may not have clinical significance. However, IHD is not a very clearly defined phenotype because IHD may have arisen for a variety of reasons, be diagnosed in many ways, and its diagnosis affected by use of medications. Imprecision in the IHD phenotype would bias toward the null, making this study, as other MR studies, more suitable for refuting causality than establishing the exact size of a causal effect. 42 Our findings may be more relevant to firstly identifying which coagulation factors are the most promising targets and secondly to population health, where a small shift in the overall population distribution may have a large impact. 43 Eighth, canalization is possible, that is, influences of genetic predictors might be damped or buffered by compensatory developmental processes. 9 However, the extent to which canalization occurs is unknown. Ninth, effects might differ by sex, and the effect of vWF might vary with ABO blood group, which cannot be assessed from the data freely available. Examination of whether the associations were mediated by lipids was not possible, because the publically available genetic data for CAD/MI and MI do not include lipids. Tenth, MR requires large samples because genetic predictors only capture a small proportion of the variance in exposures. 44 However, explaining all the variance in the coagulation factors would invalidate an instrument because it would be equivalent to the coagulation factor and be equally confounded. Taking advantage of large publicly available studies enables a cost-efficient, well-powered study. 28, 29 Replication in other studies, using different genetic predictors is required.
Our study adds to the limited evidence concerning the role of coagulation factors in IHD and MI and suggests that ETP and thromboxane A synthase might play a role, but d-dimer, tPA, and PAI-1 probably do not. However, IHD is a complex phenotype, so examining the role of these factors, and related factors, such as ADP, in more precisely defined phenotypes would be worthwhile. Given the multiple functions of thrombin, 45 several pathways might exist. First, thrombin can activate FV, FVIII, FXI, and FXIII and convert soluble fibrinogen into insoluble fibrin, which forms fibrin clots. 11 However, FV, FXI, and FXIII were not associated with IHD or MI using gene-based tests. A previous MR study also suggests that fibrinogen plays no role in IHD. 46 Second, prothrombin fragments are positively associated with plasma oxidized LDL, suggesting a potential interplay with lipids. 47 However, ETP did not affect lipids detrimentally here. Thrombin is converted from prothrombin, whose biosynthesis is vitamin K dependent. 48 ETP is lowered by vitamin K antagonists. 49 Consistently, vitamin K is positively associated with IHD in an MR study. 50 In contrast, our study does not support fibrinolytic activity as having a role in IHD or MI because fibrinolytic activity is largely determined by the balance between tPA and its natural, fast-acting inhibitor, PAI-1, 28 and our findings do not corroborate a role of tPA or PAI-1 in IHD or MI. Enalapril, which improves fibrinolytic activity, 51 did not reduce cardiovascular disease events in a randomized controlled trial. 52 As regards vWF and FVIII, it is uncertain whether they affect IHD or MI or whether associations are an unidentified attribute of ABO blood group, although the vWF gene was associated with IHD (Table 3) . Therapeutics targeting vWF are being investigated. 12 Understanding the role of ABO blood group in IHD and MI might explain the findings here and generate additional causal insights. The gene TBXAS1 was associated with IHD and MI and is targeted by existing therapeutics, such as Ridogrel, Dazoxiben, and NM-702. Few trials have assessed their effects on IHD, although Ridogrel was more effective than aspirin in preventing new ischemic events in a randomized controlled trial.
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CONCLUSIONS
Our findings do not clearly corroborate observed positive associations of d-dimer, tPA, and PAI-1 with CAD/ MI, or rule out the possibility of a role in specific IHDor MI-related phenotypes, but suggest that ETP and thromboxane A synthase might potentially play a role in IHD and MI. Whether vWF and FVIII affect IHD and MI or whether associations could be an unidentified attribute of ABO blood group remains to be clarified. Assessment of the role of the drivers and consequences of ETP and thromboxane A 2 and of factors targeting their genes in IHD and MI, as well as clarifying the role of ABO blood group, should be worthwhile, with relevance to prevention and treatment of IHD.
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